Navigation Links
Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Date:8/14/2008

m a preclinical study evaluating PCI-32765, an

orally available, selective inhibitor of Bruton's tyrosine kinase,

or Btk, in collagen induced arthritis, an established animal model

for rheumatoid arthritis (RA). Treatment of animals with advanced

disease, with PCI-32765 reduced inflammation and induced regression

of disease.

* Filed an investigational new drug (IND) application for PCI-27483, a

small molecule inhibitor of Factor VIIa being developed both for the

treatment of thrombotic complications of cancer and as an

anti-cancer agent.

* Plan to complete enrollment and evaluation of a Phase 1 trial in

normal volunteers with our Factor VIIa inhibitor, PCI-27483, in the

fourth quarter of calendar 2008.

* Plan to initiate a Phase 1 trial with our oral Btk inhibitor,

PCI-32765, in patients with recurrent B-cell lymphoma in the fourth

quarter of calendar 2008. This study is designed to evaluate safety

and efficacy using a novel pharmacodynamic biomarker.

* Plans are underway to design and conduct a pivotal Phase 3 trial

with motexafin gadolinium in patients with brain metastases from

non-small cell lung cancer receiving whole brain radiation and

stereotactic radiosurgery. This trial is anticipated to begin in the

first half of calendar 2009.

Conference Call and Webcast Details

The Company will hold a conference call today at 4:30 p.m. EDT to discuss fiscal 2008 year-end financial results and achievements and fiscal 2009 guidance. To participate in the conference call, please dial 800-497-0451 for domestic callers and 706-758-3306 for international callers and reference conference passcode 59146626. To access the live audio broadcast or the subsequent archived recording, log on to

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
2. Pharmacyclics Announces It Received Nasdaq Notification
3. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 HIGHLIGHTS:Q2 2015 Results ... , Reported sales were $697 million compared to ... grew organically by 8%, and changes in foreign currency ... sales by 1%. , By business unit, organic ... and 11% in SAFC Commercial. , Reported diluted ...
(Date:7/30/2015)... ... ... its 2015 growth plan and as a follow up to the recently announced expansion of ... pleased to announce that it has begun construction on a new Microbiological Laboratory. The new ... dedicated to basic USP 51, USP 61, and USP 62 testing specific to raw materials. ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... for the second quarter of 2015. CEO ... and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in ... - Performance drivers - ...
(Date:7/29/2015)... -- According to a new market research report, ... (2015-2020), , published by Mordor Intelligence, the Global market is ... of 2020, with North America being ... the global market size. The Global market for Stem Cells ... the period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) , ...
Breaking Biology Technology:Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3
... of the Israeli,scientists, in a recent survey on creativity, ... them into a creative state and keep,them in this ... Project Mind Foundation and conducted by TNS Teleseker, the,survey ... was raised,one fifth of the total sample expressed a ...
... AMDL, Inc.,(Amex: ADL ), headquartered in ... Jilin, China, is a vertically integrated specialty,pharmaceutical ... Inc. ("JPI"), AMDL engages in the research, ... AMDL announced,that it has entered into an ...
... 2008 BioSpace, the world,s,leading online bioscience job board ... NC(TM) Career Fair on Thursday, May 1, 2008. The ... 11 am to 4 pm., (Logo: http://www.newscom.com/cgi-bin/prnh/20080222/CLF013LOGO ... Carolina will attend the,biotech job fair to meet in ...
Cached Biology Technology:Project Mind Survey of Israeli Ph.D. Scientists Favors a New Standard of Creativity in Science 2Project Mind Survey of Israeli Ph.D. Scientists Favors a New Standard of Creativity in Science 3AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries 2AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries 3Bioscience Career Fair in North Carolina Expected to Attract Well Qualified Job Seekers 2
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs ... announcing its acquisition of Avid Nano. Avid Nano ... scattering (DLS) systems.    Also today, ... fastest and easiest to use protein sizing system. ... measures a protein,s hydrodynamic size, size distribution, aggregation ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... be having a negative effect on pinyon pine reproduction, ... same woodland ecosystems, says a University of Colorado Boulder-led ... seed cone production declined by an average of about ... and northwestern Oklahoma over the past four decades, said ...
... in the Journal of Applied Physiology, Nutrition, and ... high fructose corn syrup (HFCS) and sucrose (table sugar) at ... fat in humans, a leading cause of non-alcoholic fatty liver ... body of science that high fructose corn syrup and table ...
... techniques may be increasing the severity of an outbreak ... in Central America and Mexico, according to a University ... current outbreak of coffee rust is the worst seen ... arrived in the region more than 40 years ago. ...
Cached Biology News:Southwest regional warming likely cause of pinyon pine cone decline, says CU study 2Southwest regional warming likely cause of pinyon pine cone decline, says CU study 3New study finds neither HFCS nor table sugar increases liver fat under 'real world' conditions 2Modern growing methods may be culprit of 'coffee rust' fungal outbreak 2Modern growing methods may be culprit of 'coffee rust' fungal outbreak 3
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Biology Products: